Press Release

Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC   SAN DIEGO, November 10, 2025 (GLOBE NEWSWIRE)…

Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine SAN DIEGO, October 22, 2025 (GLOBE…

Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI)…

Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference   SAN DIEGO, CA., September 2, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”…

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option SAN DIEGO, CA., August 21, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE…

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering SAN DIEGO, CA., August 20, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a…

Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55…

Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma. SAN DIEGO, July 29, 2025…

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (“Calidi”…

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds   SAN DIEGO, July 9, 2025 — Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a…

Calidi Biotherapeutics Announces Shareholder Letter from CEO SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of…

Calidi Biotherapeutics Presents Systemic Oncolytic platform with CD55-Enhanced Expression and IL-15 Superagonist Payload at ASCO Annual Meeting San Diego, CA – June 2, 2025 — Calidi Biotherapeutics Inc. (NYSE American:…

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience Announced…

SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the…

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that…

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the…

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to…

SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering targeted antitumor virotherapies, announced today that the U.S. Food and…